



## Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

January 3, 2024

SOMERSET, N.J.--(BUSINESS WIRE)--Jan. 3, 2024-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech's existing autologous CAR-T cell therapy candidate, LB2102 ([NCT05680922](https://clinicaltrials.gov/ct2/show/NCT05680922)).<sup>1</sup> Under the terms of the license agreement, Legend Biotech will receive a \$100 million upfront cash payment.

### About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at <https://legendbiotech.com> and follow us on [X \(formerly Twitter\)](#) and [LinkedIn](#).

### References

<sup>1</sup> [ClinicalTrials.gov](https://clinicaltrials.gov). *DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer*. Available at: <https://classic.clinicaltrials.gov/ct2/show/NCT05680922>. Last accessed Nov 2023.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240103368335/en/): <https://www.businesswire.com/news/home/20240103368335/en/>

### Press contact:

Alexandra Ventura, Corporate Communications & Investor Relations, Legend Biotech  
[alex.ventura@legendbiotech.com](mailto:alex.ventura@legendbiotech.com)  
732-850-5598

### Investor contact:

Jessie Yeung, Head of Investor Relations & Public Relations, Legend Biotech  
[jessie.yeung@legendbiotech.com](mailto:jessie.yeung@legendbiotech.com)

Source: Legend Biotech Corporation